BeiGene and Novartis Make Late-Stage Progress against Liver Cancer

BeiGene and Novartis Make Late-Stage Progress against Liver Cancer

Source: 
BioSpace
snippet: 

BeiGene and Novartis' unresectable hepatocellular carcinoma treatment is gaining ground as a potential treatment for advanced liver cancer. In the Phase III RATIONALE 301 trial of Tislelizumab as a first-line treatment, the drug met its primary endpoint of non-inferior overall survival compared to sorafenib alone.